{"id":32245,"date":"2025-05-20T17:41:54","date_gmt":"2025-05-20T12:11:54","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32245"},"modified":"2025-05-26T12:39:24","modified_gmt":"2025-05-26T07:09:24","slug":"pharma-news-for-incyte-abbvie-merck","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck","title":{"rendered":"Incyte\u2019s ZYNYZ Approved as First-Line Treatment for Advanced Anal Cancer; Amneal Gets FDA Nod for BREKIYA for Migraines; FDA Accepts Travere\u2019s sNDA for FILSPARI in FSGS; AbbVie\u2019s EMRELIS Approved for Advanced NSCLC With High c-Met; Merck\u2019s WELIREG Approved for Advanced PPGL in Patients 12+"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ef6a6853d36\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ef6a6853d36\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck\/#Incytes_ZYNYZ_Approved_by_FDA_as_First-Line_Treatment_for_Advanced_Anal_Cancer\" >Incyte\u2019s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck\/#Amneal_Wins_FDA_Nod_for_BREKIYA_for_Migraines_and_Cluster_Headaches\" >Amneal Wins FDA Nod for BREKIYA for Migraines and Cluster Headaches<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck\/#FDA_Accepts_Traveres_sNDA_for_FILSPARI_in_FSGS\" >FDA Accepts Travere\u2019s sNDA for FILSPARI in FSGS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck\/#AbbVies_EMRELIS_Approved_by_FDA_for_Advanced_NSCLC_With_High_c-Met\" >AbbVie\u2019s EMRELIS Approved by FDA for Advanced NSCLC With High c-Met<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck\/#Mercks_WELIREG_Approved_by_FDA_for_Advanced_PPGL_in_Patients_Aged_12\" >Merck\u2019s WELIREG Approved by FDA for Advanced PPGL in Patients Aged 12+<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-incyte-s-zynyz-approved-by-fda-as-first-line-treatment-for-advanced-anal-cancer\"><span class=\"ez-toc-section\" id=\"Incytes_ZYNYZ_Approved_by_FDA_as_First-Line_Treatment_for_Advanced_Anal_Cancer\"><\/span>Incyte\u2019s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA approved <strong>ZYNYZ (retifanlimab-dlwr)<\/strong>, a PD-1 inhibitor developed by Incyte, for the treatment of adult patients with inoperable locally recurrent or <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-cutaneous-squamous-cell-carcinoma-market\"><strong>metastatic squamous cell carcinoma of the anal canal (SCAC)<\/strong><\/a><strong>. <\/strong>The approval includes two indications, in combination with carboplatin and paclitaxel chemotherapy as a first-line treatment, and as monotherapy for patients whose disease progressed on or who are intolerant to platinum-based therapy. This milestone is based on data from the Phase III POD1UM-303\/InterAACT2 and Phase II POD1UM-202 trials, which demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) with the combination therapy and meaningful responses with monotherapy.<\/p>\n\n\n\n<p>According to POD1UM-303\/InterAACT2 results, the ZYNYZ-chemotherapy group showed a 37% reduction in risk of progression or death (P=0.0006) and achieved a median PFS of 9.3 months compared to 7.4 months in the placebo group. The trial also showed a 6.2-month improvement in OS (P=0.0273) at interim analysis. Meanwhile, the monotherapy study POD1UM-202 demonstrated a 14% objective response rate (ORR) and a 49% disease control rate. Safety profiles for both regimens aligned with known risks associated with PD-1 inhibitors, with serious adverse reactions occurring in 47% of patients on combination therapy and 40% on monotherapy.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Incyte CEO <\/em><strong><em>Herv\u00e9 Hoppenot<\/em><\/strong><em> commented, &#8220;The FDA approval of ZYNYZ marks a pivotal moment, bringing effective combination and monotherapy treatment options to patients with advanced anal cancer after decades of limited innovation. At Incyte, we focus our efforts where we can make the biggest impact for patients. I am proud of our scientists and development teams for their perseverance in delivering the first approved PD-1 inhibitor to U.S. patients with SCAC.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Dr. Marwan Fakih<\/em><\/strong><em> of City of Hope added, &#8220;Patients with inoperable locally recurrent or metastatic anal cancer have historically faced poor five-year survival rates and limited treatment options. The POD1UM data highlight the potential of ZYNYZ to be a meaningful new option, and notably demonstrate that the addition of ZYNYZ to platinum-based chemotherapy significantly improves progression-free survival.&#8221; <\/em><strong><em>David Winterflood<\/em><\/strong><em>, CEO of the Anal Cancer Foundation, also remarked on the significance of the approval: &#8220;The approval of ZYNYZ marks a step forward for advanced SCAC treatment, brings attention to a long-overlooked condition with limited treatment options and offers patients whose anal cancer has returned or spread an option to treat their disease.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Incyte has also expanded its regulatory efforts globally, with submissions for <strong>Marketing Authorization in Europe<\/strong> and a <strong>J-NDA in Japan<\/strong> now under review.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-amneal-wins-fda-nod-for-brekiya-for-migraines-and-cluster-headaches\"><span class=\"ez-toc-section\" id=\"Amneal_Wins_FDA_Nod_for_BREKIYA_for_Migraines_and_Cluster_Headaches\"><\/span>Amneal Wins FDA Nod for BREKIYA for Migraines and Cluster Headaches<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Amneal Pharmaceuticals, Inc.<\/strong> has received FDA approval for <strong>BREKIYA (dihydroergotamine mesylate) injection<\/strong>, marking a major milestone in the treatment of migraine and cluster headaches. BREKIYA is the <em>first and only DHE autoinjector<\/em> designed for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/migraine-market\"><strong>acute treatment of migraine with or without aura<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/cluster-headache-market\"><strong>cluster headaches in adults<\/strong><\/a>. Unlike traditional DHE therapies that require administration in hospitals via intravenous routes, BREKIYA is a <em>ready-to-use, subcutaneous autoinjector<\/em> that allows patients to self-administer their medication at home, offering convenience, faster relief, and greater independence. The product is expected to be available in the <strong>second half of 2025<\/strong> for appropriate patients.<\/p>\n\n\n\n<p>The autoinjector provides sustained pain relief for those who experience inadequate response to oral therapies or deal with nausea, vomiting, or gastroparesis during attacks. Importantly, BREKIYA requires no refrigeration, assembly, or priming, and is administered via a single injection into the thigh. Given the limited treatment options for cluster headache, this new delivery format offers a promising solution for a widely underserved patient population.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Joe Renda, Senior Vice President and Chief Commercial Officer<\/em><\/strong><em> \u2013 Specialty at Amneal, emphasized the therapeutic innovation BREKIYA represents: \u201cWe are thrilled to offer the first and only ready-to-use autoinjector for patients suffering from acute migraine and cluster headaches. Physicians are familiar with DHE, which is an effective and well-established therapy that provides sustained relief for headaches. Our single-dose autoinjector represents an innovative therapeutic option for patients that allows for quick self-administration of the medication during these painful attacks without visiting the emergency room.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>With nearly <strong>39 million Americans living with migraine<\/strong> and <strong>up to one million affected by cluster headaches<\/strong>, BREKIYA&#8217;s approval could significantly impact emergency room burden, where headache remains a top cause of visits. However, the use of BREKIYA comes with strict safety guidelines. Patients are advised not to take it alongside strong CYP3A4 inhibitors, and it is contraindicated in individuals with certain cardiovascular conditions, liver or kidney issues, and during pregnancy or breastfeeding. Proper medical guidance is essential before initiating treatment with BREKIYA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-accepts-travere-s-snda-for-filspari-in-fsgs\"><span class=\"ez-toc-section\" id=\"FDA_Accepts_Traveres_sNDA_for_FILSPARI_in_FSGS\"><\/span>FDA Accepts Travere\u2019s sNDA for FILSPARI in FSGS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Travere Therapeutics, Inc<\/strong>. announced that the <strong>FDA <\/strong>has accepted its supplemental <strong>New Drug Application (sNDA) <\/strong>for <strong>FILSPARI (sparsentan)<\/strong> for the treatment of<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-market\"><strong>focal segmental glomerulosclerosis (FSGS)<\/strong><\/a><strong>,<\/strong> a rare and serious kidney disorder. If approved, FILSPARI would become the first and only FDA-approved treatment for FSGS, which is one of the leading causes of kidney failure. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026, and plans to convene an advisory committee to review the application.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cToday marks an important milestone in our mission to transform care for patients with rare kidney disease,\u201d <\/em><strong><em>said Eric Dube, <\/em><\/strong><em>Ph.D., president and chief executive officer of Travere Therapeutics. \u201cWe are one step closer to potentially delivering the first approved treatment for people living with FSGS, a leading cause of kidney failure and devastating condition that urgently needs new treatment options.\u201d He further added, \u201cWith this progress, we continue our commitment to the FSGS community who has been waiting so long for an effective medicine. We look forward to the upcoming review process.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>FILSPARI is a non-immunosuppressive, oral treatment designed to directly target podocyte injury by simultaneously blocking the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). It is currently approved for use in slowing kidney function decline in patients with IgA nephropathy. The application for FSGS is backed by strong clinical evidence from the Phase III DUPLEX Study and Phase II DUET Study, two of the most comprehensive interventional trials conducted in patients with FSGS. These studies showed FILSPARI\u2019s superiority in reducing proteinuria compared to irbesartan, the current standard of care.<\/p>\n\n\n\n<p>The clinical data not only confirmed the efficacy of FILSPARI in lowering protein levels in urine but also aligned with findings from the PARASOL workgroup, which demonstrated that long-term reduction in proteinuria significantly correlates with decreased risk of kidney failure. The drug was well-tolerated, and its safety profile was consistent with that of maximally dosed irbesartan, supporting its potential as a safe and effective new option for patients with FSGS.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbvie-s-emrelis-approved-by-fda-for-advanced-nsclc-with-high-c-met\"><span class=\"ez-toc-section\" id=\"AbbVies_EMRELIS_Approved_by_FDA_for_Advanced_NSCLC_With_High_c-Met\"><\/span>AbbVie\u2019s EMRELIS Approved by FDA for Advanced NSCLC With High c-Met<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AbbVie<\/strong> announced that the <strong>FDA <\/strong>has granted accelerated approval to <strong>EMRELIS (telisotuzumab vedotin-tllv) <\/strong>for the treatment of adult patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><strong>locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC)<\/strong><\/a><strong> <\/strong>who have high c-Met protein overexpression and have received prior systemic therapy. EMRELIS is the first and only treatment approved for this specific patient population, which typically faces a poor prognosis and limited options.<\/p>\n\n\n\n<p>High c-Met overexpression is defined by \u2265 50% of tumor cells showing strong (3+) staining, as determined by the FDA-approved Roche VENTANA\u00ae MET (SP44) RxDx Assay companion diagnostic. Approximately 25% of advanced EGFR wild-type, non-squamous NSCLC patients exhibit c-Met overexpression, with about half qualifying as high overexpressers.<\/p>\n\n\n\n<p>EMRELIS is a c-Met-directed antibody-drug conjugate (ADC) designed to deliver a potent cytotoxic payload directly to c-Met-expressing tumor cells. The accelerated approval was based on data from the Phase II LUMINOSITY study, which demonstrated a 35% overall response rate (ORR) and a median duration of response (DOR) of 7.2 months in patients with high c-Met overexpression. The safety profile was manageable, with common adverse events including peripheral neuropathy, fatigue, decreased appetite, and peripheral edema.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis approval represents a critical advancement in personalized lung cancer treatment for patients with high c-Met overexpressing NSCLC who have historically had limited options,\u201d said<strong> Jonathan Goldman, MD, <\/strong>UCLA. AbbVie\u2019s executive leadership highlighted EMRELIS as their first internally developed FDA-approved solid tumor therapy, emphasizing the company\u2019s commitment to precision oncology.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Further confirmation of clinical benefit is being evaluated in the ongoing global Phase III TeliMET NSCLC-01 trial. The FDA also granted EMRELIS Breakthrough Therapy Designation in 2021 based on promising early data.<\/p>\n\n\n\n<p>Lung cancer remains the leading cause of cancer-related mortality worldwide, underscoring the urgent need for new targeted therapies like EMRELIS to improve outcomes in difficult-to-treat populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-merck-s-welireg-approved-by-fda-for-advanced-ppgl-in-patients-aged-12\"><span class=\"ez-toc-section\" id=\"Mercks_WELIREG_Approved_by_FDA_for_Advanced_PPGL_in_Patients_Aged_12\"><\/span>Merck\u2019s WELIREG Approved by FDA for Advanced PPGL in Patients Aged 12+<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Merck,<\/strong> known as <strong>MSD <\/strong>outside the U.S. and Canada, announced FDA approval of <strong>WELIREG <\/strong>(belzutifan), an oral hypoxia-inducible factor-2 alpha inhibitor, for the treatment of adult and pediatric patients aged 12 and older with<strong> locally advanced, unresectable, or metastatic <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pheochromocytomas-and-paragangliomas-pcpg-market\"><strong>pheochromocytoma or paraganglioma (PPGL)<\/strong><\/a>. PPGL are rare neuroendocrine tumors arising from similar tissues: pheochromocytomas originate in the adrenal gland, while paragangliomas develop outside the adrenal gland. These tumors may be driven by genetic syndromes or mutations, complicating diagnosis and management.<\/p>\n\n\n\n<p>The approval is based on results from the single-arm Phase II LITESPARK-015 trial (NCT04924075), which enrolled 72 patients with measurable disease and controlled blood pressure. The primary endpoint was objective response rate (ORR) assessed by blinded independent central review (BICR) using RECIST v1.1 criteria. WELIREG was administered at 120 mg once daily until disease progression or unacceptable toxicity.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis approval introduces the only approved non-surgical treatment option for patients with locally advanced or metastatic PPGL, addressing a critical unmet need in a rare and challenging disease area,\u201d said <strong>Dr. Camilo Jimenez,<\/strong> MD Anderson Cancer Center.<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em><strong>Dr. Marjorie Green,<\/strong> Merck\u2019s senior VP of oncology, highlighted that this represents the third FDA-approved indication for WELIREG, underscoring Merck\u2019s commitment to innovative therapies for rare cancers. The WELIREG label includes a boxed warning for embryo-fetal toxicity; pregnancy must be ruled out before treatment, and effective non-hormonal contraception is required during therapy. WELIREG may cause severe anemia and hypoxia, necessitating careful monitoring and possible intervention.<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Incyte\u2019s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer The FDA approved ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by Incyte, for the treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The approval includes two indications, in combination with carboplatin and paclitaxel chemotherapy [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":32246,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[137,4471,204,704,19741,19747,19744,349,1193,6441,6439,420,6733,979,6734,21479,12557,639,5789],"industry":[17225],"therapeutic_areas":[17230,17245,17228,17234],"class_list":["post-32245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer","tag-cluster-headache","tag-delveinsight","tag-fda","tag-focal-segmental-glomerulosclerosis","tag-focal-segmental-glomerulosclerosis-clinical-trials","tag-focal-segmental-glomerulosclerosis-treatment","tag-latest-pharma-news","tag-migraine","tag-migraine-therapy","tag-migraine-treatment","tag-news","tag-non-small-cell-lung-cancer","tag-non-small-cell-lung-cancer-nsclc","tag-non-small-cell-lung-cancer-pipeline-market","tag-non-small-cell-lung-cancer-treatment","tag-non-small-cell-lung-cancer-treatment-market","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Incyte, AbbVie, Merck<\/title>\n<meta name=\"description\" content=\"Incyte\u2019s ZYNYZ Approved; Amneal\u2019s BREKIYA Approved; Travere\u2019s FILSPARI; AbbVie\u2019s EMRELIS; Merck\u2019s WELIREG for Advanced PPGL\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Incyte, AbbVie, Merck\" \/>\n<meta property=\"og:description\" content=\"Incyte\u2019s ZYNYZ Approved; Amneal\u2019s BREKIYA Approved; Travere\u2019s FILSPARI; AbbVie\u2019s EMRELIS; Merck\u2019s WELIREG for Advanced PPGL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T12:11:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-26T07:09:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/20173724\/20-05-2025.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Incyte, AbbVie, Merck","description":"Incyte\u2019s ZYNYZ Approved; Amneal\u2019s BREKIYA Approved; Travere\u2019s FILSPARI; AbbVie\u2019s EMRELIS; Merck\u2019s WELIREG for Advanced PPGL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Incyte, AbbVie, Merck","og_description":"Incyte\u2019s ZYNYZ Approved; Amneal\u2019s BREKIYA Approved; Travere\u2019s FILSPARI; AbbVie\u2019s EMRELIS; Merck\u2019s WELIREG for Advanced PPGL","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-05-20T12:11:54+00:00","article_modified_time":"2025-05-26T07:09:24+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/20173724\/20-05-2025.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck","name":"Pharma News | Incyte, AbbVie, Merck","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/20173724\/20-05-2025.png","datePublished":"2025-05-20T12:11:54+00:00","dateModified":"2025-05-26T07:09:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Incyte\u2019s ZYNYZ Approved; Amneal\u2019s BREKIYA Approved; Travere\u2019s FILSPARI; AbbVie\u2019s EMRELIS; Merck\u2019s WELIREG for Advanced PPGL","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-abbvie-merck#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/20173724\/20-05-2025.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/20173724\/20-05-2025.png","width":772,"height":482,"caption":"pharma-news-for-incyte-abbvie-merck"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/20173724\/20-05-2025-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cluster headache<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Focal Segmental Glomerulosclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Focal Segmental Glomerulosclerosis clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Focal Segmental Glomerulosclerosis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">non-small cell lung cancer treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cluster headache<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Focal Segmental Glomerulosclerosis<\/span>","<span class=\"advgb-post-tax-term\">Focal Segmental Glomerulosclerosis clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Focal Segmental Glomerulosclerosis treatment<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Migraine<\/span>","<span class=\"advgb-post-tax-term\">Migraine therapy<\/span>","<span class=\"advgb-post-tax-term\">Migraine treatment<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer Pipeline Market<\/span>","<span class=\"advgb-post-tax-term\">non-small cell lung cancer treatment<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on May 20, 2025","modified":"Updated on May 26, 2025"},"absolute_dates_time":{"created":"Posted on May 20, 2025 5:41 pm","modified":"Updated on May 26, 2025 12:39 pm"},"featured_img_caption":"pharma-news-for-incyte-abbvie-merck\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32245"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32245\/revisions"}],"predecessor-version":[{"id":32294,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32245\/revisions\/32294"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32246"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32245"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32245"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}